Targeting immune markers on Ewing sarcoma tumors
Attacking the Immunopeptidome of Ewing Sarcoma
['FUNDING_U01'] · STANFORD UNIVERSITY · NIH-11159641
This project aims to develop immune-based therapies that target proteins commonly found on Ewing sarcoma tumors in children and young adults.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11159641 on ClinicalTrials.gov |
What this research studies
Researchers are mapping the peptides (the immunopeptidome) shown on Ewing sarcoma cells to find proteins the immune system can recognize, focusing on peptides from LIPI and IGF2BP1 that appear on HLA-A2 positive tumors. They will use laboratory techniques including mass spectrometry and immune assays to confirm which peptides are presented and can trigger T cells. The team plans to generate and test immune receptors or T cells that specifically bind those tumor peptides and to evaluate safety and tumor-killing activity in preclinical models. Successful preclinical work would support moving toward early clinical testing in patients with relapsed or hard-to-treat Ewing sarcoma.
Who could benefit from this research
Good fit: Ideal candidates would be people (children or young adults) with Ewing sarcoma whose tumors express the target proteins and who are HLA-A2 positive, especially those with recurrent or metastatic disease.
Not a fit: Patients whose tumors do not present the target peptides or who are not HLA-A2 positive are unlikely to benefit from these specific targeted approaches.
Why it matters
Potential benefit: If successful, this work could lead to new targeted immune therapies that more effectively attack Ewing sarcoma cells while reducing long-term toxic chemotherapy effects.
How similar studies have performed: Immune and adoptive cell therapies have shown strong results in some adult cancers, but applying peptide-targeted immunotherapies to low-mutation pediatric tumors like Ewing sarcoma is relatively new and not yet proven in patients.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACKALL, CRYSTAL — STANFORD UNIVERSITY
- Study coordinator: MACKALL, CRYSTAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.